PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients

L. Richeldi (Southampton, United Kingdom)

Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Session: Idiopathic pulmonary fibrosis (IPF): treatment highlights
Session type: Oral Presentation
Number: 3400
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Richeldi (Southampton, United Kingdom). PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients. 3400

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: